# Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

> **NCT01882374** · PHASE2 · WITHDRAWN · sponsor: **Tarix Pharmaceuticals**

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** TXA127

## Key facts

- **NCT ID:** NCT01882374
- **Lead sponsor:** Tarix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in drug product development strategy
- **Last updated:** 2016-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01882374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01882374, "Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01882374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*